Skip to main content
Top
Published in: BMC Infectious Diseases 1/2019

Open Access 01-12-2019 | Antibiotic | Research article

Risk factors for mortality in patients with Stenotrophomonas maltophilia bacteremia and clinical impact of quinolone–resistant strains

Authors: Eun Jin Kim, Yong Chan Kim, Jin Young Ahn, Su Jin Jeong, Nam Su Ku, Jun Yong Choi, Joon-Sup Yeom, Young Goo Song

Published in: BMC Infectious Diseases | Issue 1/2019

Login to get access

Abstract

Background

Stenotrophomonas maltophilia is an important nosocomial pathogen. This pathogen has intrinsic or acquired resistance to a number of antibiotics classes. Furthermore, Stenotrophomonas infections have been associated with high mortality, mainly in immunocompromised patients. Accordingly, we conducted a retrospective cohort study on the clinical data, microbiological characteristics, and outcomes of patients with S. maltophilia (SM) bacteremia.

Methods

A retrospective cohort study was conducted at two tertiary care referral hospitals in Seoul, South Korea. Data were collected between January 2006 and December 2015 from electric medical records. Our analysis aimed to identify the risk factors associated with crude mortality, as well as the predictive factors of quinolone-resistant strains in SM bacteremia patients.

Results

A total of 126 bacteremia patients were enrolled in the study. The mortality rate was 65.1%. On multivariable analysis, hypoalbuminemia (odds ratio [OR], 5.090; 95% confidence interval [CI], 1.321–19.621; P = 0.018), hematologic malignancy (OR, 35.567; 95% CI, 2.517–502.515; P = 0.008) and quinolone-resistant strains (OR, 7.785; 95% CI, 1.278–47.432; P = 0.026) were independent risk factors for mortality. Alternatively, usage of an empirical regimen with quinolone (OR, 0.172; 95% CI, 0.034–0.875; P = 0.034) was an independent protective factor for mortality. The multivariable analysis of predictive factors revealed that high Charlson comorbidity index (OR, 1.190; 95% CI, 1.040–1.361; P = 0.011) and indwelling of a central venous catheter (CVC) (OR, 3.303; 95% CI, 1.194–9.139; P = 0.021) were independent predisposing factors associated with quinolone-resistant strains in SM bacteremia patients.

Conclusions

Our findings suggest that a high Charlson comorbidity score and indwelling of a CVC were significantly independent predictors of quinolone-resistant strains in SM bacteremia patients. Therefore, we need to carefully consider the antibiotic use in SM bacteremia patients with these predictive factors.
Appendix
Available only for authorised users
Literature
1.
go back to reference Denton M, Kerr KG. Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia. Clin Microbiol Rev. 1998;11(1):57–80.CrossRef Denton M, Kerr KG. Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia. Clin Microbiol Rev. 1998;11(1):57–80.CrossRef
2.
go back to reference Hoefel D, Monis PT, Grooby WL, Andrews S, Saint CP. Profiling bacterial survival through a water treatment process and subsequent distribution system. J Appl Microbiol. 2005;99(1):175–86.CrossRef Hoefel D, Monis PT, Grooby WL, Andrews S, Saint CP. Profiling bacterial survival through a water treatment process and subsequent distribution system. J Appl Microbiol. 2005;99(1):175–86.CrossRef
3.
go back to reference Falagas ME, Kastoris AC, Vouloumanou EK, Rafailidis PI, Kapaskelis AM, Dimopoulos G. Attributable mortality of Stenotrophomonas maltophilia infections: a systematic review of the literature. Future Microbiol. 2009;4(9):1103–9.CrossRef Falagas ME, Kastoris AC, Vouloumanou EK, Rafailidis PI, Kapaskelis AM, Dimopoulos G. Attributable mortality of Stenotrophomonas maltophilia infections: a systematic review of the literature. Future Microbiol. 2009;4(9):1103–9.CrossRef
4.
go back to reference Micozzi A, Venditti M, Monaco M, Friedrich A, Taglietti F, Santilli S, et al. Bacteremia due to Stenotrophomonas maltophilia in patients with hematologic malignancies. Clin Infect Dis. 2000;31(3):705–11.CrossRef Micozzi A, Venditti M, Monaco M, Friedrich A, Taglietti F, Santilli S, et al. Bacteremia due to Stenotrophomonas maltophilia in patients with hematologic malignancies. Clin Infect Dis. 2000;31(3):705–11.CrossRef
5.
go back to reference Labarca JA, Leber AL, Kern VL, Territo MC, Brankovic LE, Bruckner DA, et al. Outbreak of Stenotrophomonas maltophilia bacteremia in allogenic bone marrow transplant patients: role of severe neutropenia and mucositis. Clin Infect Dis. 2000;30(1):195–7.CrossRef Labarca JA, Leber AL, Kern VL, Territo MC, Brankovic LE, Bruckner DA, et al. Outbreak of Stenotrophomonas maltophilia bacteremia in allogenic bone marrow transplant patients: role of severe neutropenia and mucositis. Clin Infect Dis. 2000;30(1):195–7.CrossRef
6.
go back to reference Gales AC, Jones RN, Forward KR, Linares J, Sader HS, Verhoef J. Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY antimicrobial surveillance program (1997-1999). Clin Infect Dis. 2001;32(Suppl 2):S104–13.CrossRef Gales AC, Jones RN, Forward KR, Linares J, Sader HS, Verhoef J. Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY antimicrobial surveillance program (1997-1999). Clin Infect Dis. 2001;32(Suppl 2):S104–13.CrossRef
7.
go back to reference Zhang L, Li XZ, Poole K. Multiple antibiotic resistance in Stenotrophomonas maltophilia: involvement of a multidrug efflux system. Antimicrob Agents Chemother. 2000;44(2):287–93.CrossRef Zhang L, Li XZ, Poole K. Multiple antibiotic resistance in Stenotrophomonas maltophilia: involvement of a multidrug efflux system. Antimicrob Agents Chemother. 2000;44(2):287–93.CrossRef
8.
go back to reference Alonso A, Martinez JL. Multiple antibiotic resistance in Stenotrophomonas maltophilia. Antimicrob Agents Chemother. 1997;41(5):1140–2.CrossRef Alonso A, Martinez JL. Multiple antibiotic resistance in Stenotrophomonas maltophilia. Antimicrob Agents Chemother. 1997;41(5):1140–2.CrossRef
9.
go back to reference Looney WJ, Narita M, Muhlemann K. Stenotrophomonas maltophilia: an emerging opportunist human pathogen. Lancet Infect Dis. 2009;9(5):312–23.CrossRef Looney WJ, Narita M, Muhlemann K. Stenotrophomonas maltophilia: an emerging opportunist human pathogen. Lancet Infect Dis. 2009;9(5):312–23.CrossRef
10.
go back to reference Sanchez MB. Antibiotic resistance in the opportunistic pathogen Stenotrophomonas maltophilia. Front Microbiol. 2015;6:658.CrossRef Sanchez MB. Antibiotic resistance in the opportunistic pathogen Stenotrophomonas maltophilia. Front Microbiol. 2015;6:658.CrossRef
11.
go back to reference Nicodemo AC, Paez JI. Antimicrobial therapy for Stenotrophomonas maltophilia infections. Eur J Clin Microbiol Infect Dis. 2007;26(4):229–37.CrossRef Nicodemo AC, Paez JI. Antimicrobial therapy for Stenotrophomonas maltophilia infections. Eur J Clin Microbiol Infect Dis. 2007;26(4):229–37.CrossRef
12.
go back to reference Chung HS, Hong SG, Kim YR, Shin KS, Whang DH, Ahn JY, et al. Antimicrobial susceptibility of stenotrophomonas maltophilia isolates from Korea, and the activity of antimicrobial combinations against the isolates. J Korean Med Sci. 2013;28(1):62–6.CrossRef Chung HS, Hong SG, Kim YR, Shin KS, Whang DH, Ahn JY, et al. Antimicrobial susceptibility of stenotrophomonas maltophilia isolates from Korea, and the activity of antimicrobial combinations against the isolates. J Korean Med Sci. 2013;28(1):62–6.CrossRef
13.
go back to reference Cho SY, Kang CI, Kim J, Ha YE, Chung DR, Lee NY, et al. Can levofloxacin be a useful alternative to trimethoprim-sulfamethoxazole for treating Stenotrophomonas maltophilia bacteremia? Antimicrob Agents Chemother. 2014;58(1):581–3.CrossRef Cho SY, Kang CI, Kim J, Ha YE, Chung DR, Lee NY, et al. Can levofloxacin be a useful alternative to trimethoprim-sulfamethoxazole for treating Stenotrophomonas maltophilia bacteremia? Antimicrob Agents Chemother. 2014;58(1):581–3.CrossRef
14.
go back to reference Bonfiglio G, Cascone C, Azzarelli C, Cafiso V, Marchetti F, Stefani S. Levofloxacin in vitro activity and time-kill evaluation of Stenotrophomonas maltophilia clinical isolates. J Antimicrob Chemother. 2000;45(1):115–7.CrossRef Bonfiglio G, Cascone C, Azzarelli C, Cafiso V, Marchetti F, Stefani S. Levofloxacin in vitro activity and time-kill evaluation of Stenotrophomonas maltophilia clinical isolates. J Antimicrob Chemother. 2000;45(1):115–7.CrossRef
15.
go back to reference Wang YL, Scipione MR, Dubrovskaya Y, Papadopoulos J. Monotherapy with fluoroquinolone or trimethoprim-sulfamethoxazole for treatment of Stenotrophomonas maltophilia infections. Antimicrob Agents Chemother. 2014;58(1):176–82.CrossRef Wang YL, Scipione MR, Dubrovskaya Y, Papadopoulos J. Monotherapy with fluoroquinolone or trimethoprim-sulfamethoxazole for treatment of Stenotrophomonas maltophilia infections. Antimicrob Agents Chemother. 2014;58(1):176–82.CrossRef
16.
go back to reference Chang YT, Lin CY, Lu PL, Lai CC, Chen TC, Chen CY, et al. Stenotrophomonas maltophilia bloodstream infection: comparison between community-onset and hospital-acquired infections. Wei mian yu gan ran za zhi. 2014;47(1):28–35.CrossRef Chang YT, Lin CY, Lu PL, Lai CC, Chen TC, Chen CY, et al. Stenotrophomonas maltophilia bloodstream infection: comparison between community-onset and hospital-acquired infections. Wei mian yu gan ran za zhi. 2014;47(1):28–35.CrossRef
17.
go back to reference Pien CJ, Kuo HY, Chang SW, Chen PR, Yeh HW, Liu CC, et al. Risk factors for levofloxacin resistance in Stenotrophomonas maltophilia from respiratory tract in a regional hospital. Wei mian yu gan ran za zhi. 2015;48(3):291–5.CrossRef Pien CJ, Kuo HY, Chang SW, Chen PR, Yeh HW, Liu CC, et al. Risk factors for levofloxacin resistance in Stenotrophomonas maltophilia from respiratory tract in a regional hospital. Wei mian yu gan ran za zhi. 2015;48(3):291–5.CrossRef
18.
go back to reference Wu H, Wang JT, Shiau YR, Wang HY, Lauderdale TL, Chang SC. A multicenter surveillance of antimicrobial resistance on Stenotrophomonas maltophilia in Taiwan. Wei mian yu gan ran za zhi. 2012;45(2):120–6.CrossRef Wu H, Wang JT, Shiau YR, Wang HY, Lauderdale TL, Chang SC. A multicenter surveillance of antimicrobial resistance on Stenotrophomonas maltophilia in Taiwan. Wei mian yu gan ran za zhi. 2012;45(2):120–6.CrossRef
19.
go back to reference Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control. 2008;36(5):309–32.CrossRef Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control. 2008;36(5):309–32.CrossRef
20.
go back to reference McGregor JC, Rich SE, Harris AD, Perencevich EN, Osih R, Lodise TP Jr, et al. A systematic review of the methods used to assess the association between appropriate antibiotic therapy and mortality in bacteremic patients. Clin Infect Dis. 2007;45(3):329–37.CrossRef McGregor JC, Rich SE, Harris AD, Perencevich EN, Osih R, Lodise TP Jr, et al. A systematic review of the methods used to assess the association between appropriate antibiotic therapy and mortality in bacteremic patients. Clin Infect Dis. 2007;45(3):329–37.CrossRef
21.
go back to reference Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83.CrossRef Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83.CrossRef
22.
go back to reference Patel JB, Cockerill FR III, Bradford PA, Eliopoulos GM, Hindler JA, Jenkins SG, et al. Clinical and laboratory standards institute. Performance standards for antimicrobial susceptibility testing; 25th informational supplementvol. 35 Number 3: CLSI; 2015: (Document M100-S124) CLSI; 2015. Patel JB, Cockerill FR III, Bradford PA, Eliopoulos GM, Hindler JA, Jenkins SG, et al. Clinical and laboratory standards institute. Performance standards for antimicrobial susceptibility testing; 25th informational supplementvol. 35 Number 3: CLSI; 2015: (Document M100-S124) CLSI; 2015.
23.
go back to reference Paez JI, Costa SF. Risk factors associated with mortality of infections caused by Stenotrophomonas maltophilia: a systematic review. J Hosp Infect. 2008;70(2):101–8.CrossRef Paez JI, Costa SF. Risk factors associated with mortality of infections caused by Stenotrophomonas maltophilia: a systematic review. J Hosp Infect. 2008;70(2):101–8.CrossRef
24.
go back to reference Baek JH, Kim CO, Jeong SJ, Ku NS, Han SH, Choi JY, et al. Clinical factors associated with acquisition of resistance to levofloxacin in Stenotrophomonas maltophilia. Yonsei Med J. 2014;55(4):987–93.CrossRef Baek JH, Kim CO, Jeong SJ, Ku NS, Han SH, Choi JY, et al. Clinical factors associated with acquisition of resistance to levofloxacin in Stenotrophomonas maltophilia. Yonsei Med J. 2014;55(4):987–93.CrossRef
25.
go back to reference Ma HY, Hung IC, Huang YH, Chang YY, Sheng WH, Wang JT, et al. Prognostic factors of health care-associated bloodstream infection in adult patients >/=40 years of age. Am J Infect Control. 2018;46(1):111–4.CrossRef Ma HY, Hung IC, Huang YH, Chang YY, Sheng WH, Wang JT, et al. Prognostic factors of health care-associated bloodstream infection in adult patients >/=40 years of age. Am J Infect Control. 2018;46(1):111–4.CrossRef
26.
go back to reference Araoka H, Baba M, Yoneyama A. Risk factors for mortality among patients with Stenotrophomonas maltophilia bacteremia in Tokyo, Japan, 1996-2009. Eur J Clin Microbiol Infect Dis. 2010;29(5):605–8.CrossRef Araoka H, Baba M, Yoneyama A. Risk factors for mortality among patients with Stenotrophomonas maltophilia bacteremia in Tokyo, Japan, 1996-2009. Eur J Clin Microbiol Infect Dis. 2010;29(5):605–8.CrossRef
27.
go back to reference Friedman ND, Korman TM, Fairley CK, Franklin JC, Spelman DW. Bacteraemia due to Stenotrophomonas maltophilia: an analysis of 45 episodes. J Infect. 2002;45(1):47–53.CrossRef Friedman ND, Korman TM, Fairley CK, Franklin JC, Spelman DW. Bacteraemia due to Stenotrophomonas maltophilia: an analysis of 45 episodes. J Infect. 2002;45(1):47–53.CrossRef
28.
go back to reference Jeon YD, Jeong WY, Kim MH, Jung IY, Ahn MY, Ann HW, et al. Risk factors for mortality in patients with Stenotrophomonas maltophilia bacteremia. Medicine. 2016;95(31):e4375.CrossRef Jeon YD, Jeong WY, Kim MH, Jung IY, Ahn MY, Ann HW, et al. Risk factors for mortality in patients with Stenotrophomonas maltophilia bacteremia. Medicine. 2016;95(31):e4375.CrossRef
29.
go back to reference Ebara H, Hagiya H, Haruki Y, Kondo E, Otsuka F. Clinical characteristics of Stenotrophomonas maltophilia bacteremia: a regional report and a review of a Japanese case series. Internal Med. 2017;56(2):137–42.CrossRef Ebara H, Hagiya H, Haruki Y, Kondo E, Otsuka F. Clinical characteristics of Stenotrophomonas maltophilia bacteremia: a regional report and a review of a Japanese case series. Internal Med. 2017;56(2):137–42.CrossRef
30.
go back to reference Sanyal SC, Mokaddas EM. The increase in carbapenem use and emergence of Stenotrophomonas maltophilia as an important nosocomial pathogen. J Chemother. 1999;11(1):28–33.CrossRef Sanyal SC, Mokaddas EM. The increase in carbapenem use and emergence of Stenotrophomonas maltophilia as an important nosocomial pathogen. J Chemother. 1999;11(1):28–33.CrossRef
Metadata
Title
Risk factors for mortality in patients with Stenotrophomonas maltophilia bacteremia and clinical impact of quinolone–resistant strains
Authors
Eun Jin Kim
Yong Chan Kim
Jin Young Ahn
Su Jin Jeong
Nam Su Ku
Jun Yong Choi
Joon-Sup Yeom
Young Goo Song
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2019
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-019-4394-4

Other articles of this Issue 1/2019

BMC Infectious Diseases 1/2019 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.